Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Eric G. Voog"'
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Supplementary tables 1 to 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b4211f3d6f9a4b9c4328e0c277e2ff
https://doi.org/10.1158/1078-0432.22472622
https://doi.org/10.1158/1078-0432.22472622
Autor:
Simon Chowdhury, Tony Golsorkhi, Simon P. Watkins, Foad Green, Melanie Dowson, Darrin Despain, Andrea Loehr, Andrew D. Simmons, Felix Y. Feng, Charles J. Ryan, Laurence E. Krieger, Celestia S. Higano, Axel S. Merseburger, Karim Fizazi, Josep Maria Piulats, Jingsong Zhang, Julie Rowe, Francesco Ricci, Ray McDermott, Alan H. Bryce, Eric G. Voog, Nicholas J. Vogelzang, Brieuc Sautois, Jeremy D. Shapiro, Akash Patnaik, David Campbell, Wassim Abida
Purpose:Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucapa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::840ec9d41ad4c90628d625e9adfc77d4
https://doi.org/10.1158/1078-0432.c.6530016
https://doi.org/10.1158/1078-0432.c.6530016
Autor:
Simon Chowdhury, Tony Golsorkhi, Simon P. Watkins, Foad Green, Melanie Dowson, Darrin Despain, Andrea Loehr, Andrew D. Simmons, Felix Y. Feng, Charles J. Ryan, Laurence E. Krieger, Celestia S. Higano, Axel S. Merseburger, Karim Fizazi, Josep Maria Piulats, Jingsong Zhang, Julie Rowe, Francesco Ricci, Ray McDermott, Alan H. Bryce, Eric G. Voog, Nicholas J. Vogelzang, Brieuc Sautois, Jeremy D. Shapiro, Akash Patnaik, David Campbell, Wassim Abida
Supplementary Figure S1. Incidence of gene alteration types for patients from TRITON2 with non-BRCA DDR gene alterations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::585bd7b467bd6ca7419878593531f6c5
https://doi.org/10.1158/1078-0432.22478694
https://doi.org/10.1158/1078-0432.22478694
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Purpose:Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0665968cd1edf97628a1303b28c4bb
https://doi.org/10.1158/1078-0432.c.6528276
https://doi.org/10.1158/1078-0432.c.6528276
Autor:
Simon Chowdhury, Tony Golsorkhi, Simon P. Watkins, Foad Green, Melanie Dowson, Darrin Despain, Andrea Loehr, Andrew D. Simmons, Felix Y. Feng, Charles J. Ryan, Laurence E. Krieger, Celestia S. Higano, Axel S. Merseburger, Karim Fizazi, Josep Maria Piulats, Jingsong Zhang, Julie Rowe, Francesco Ricci, Ray McDermott, Alan H. Bryce, Eric G. Voog, Nicholas J. Vogelzang, Brieuc Sautois, Jeremy D. Shapiro, Akash Patnaik, David Campbell, Wassim Abida
Suppl Fig Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4daa79f16b2712754d1737b3dcffdf51
https://doi.org/10.1158/1078-0432.22478667.v1
https://doi.org/10.1158/1078-0432.22478667.v1
Autor:
Toni K. Choueiri, Paul B. Robbins, Stan Krulewicz, Alessandra di Pietro, Bo Huang, Aly-Khan A. Lalani, Bradley A. McGregor, Nikolay Kislov, Elaine T. Lam, Eric G. Voog, Lance C. Pagliaro, Laurence Albiges, John B.A.G. Haanen, James Larkin, Martin H. Voss, Brian I. Rini, Mehmet A. Bilen
Purpose:To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib.Experimental Design:Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3ad6b0d41f43263ce718f6b78b6354
https://doi.org/10.1158/1078-0432.c.6531050.v1
https://doi.org/10.1158/1078-0432.c.6531050.v1
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Supplementary Figure 1. Complementary survival curves for the whole cohort (n=30). (A) Event Free Survival (EFR); (B) Time to new treatment (TTNT); (C) Duration of response (DOR). Supplementary Figure 2. Progression Free Survival and Overall Survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5b9305062769531748ccdd76584f24
https://doi.org/10.1158/1078-0432.22472625
https://doi.org/10.1158/1078-0432.22472625
Autor:
Simon Chowdhury, Tony Golsorkhi, Simon P. Watkins, Foad Green, Melanie Dowson, Darrin Despain, Andrea Loehr, Andrew D. Simmons, Felix Y. Feng, Charles J. Ryan, Laurence E. Krieger, Celestia S. Higano, Axel S. Merseburger, Karim Fizazi, Josep Maria Piulats, Jingsong Zhang, Julie Rowe, Francesco Ricci, Ray McDermott, Alan H. Bryce, Eric G. Voog, Nicholas J. Vogelzang, Brieuc Sautois, Jeremy D. Shapiro, Akash Patnaik, David Campbell, Wassim Abida
Supplementary Figure S3. Change in PSA levels over time in patients with an ATM alteration (A), CDK12 alteration (B), CHEK2 alteration (C), or other DDR gene alteration (D). Patients with a PSA response are indicated with closed triangles; patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e2195c94239b2007e979baca2bf7ab
https://doi.org/10.1158/1078-0432.22478673
https://doi.org/10.1158/1078-0432.22478673
Autor:
Toni K. Choueiri, Paul B. Robbins, Stan Krulewicz, Alessandra di Pietro, Bo Huang, Aly-Khan A. Lalani, Bradley A. McGregor, Nikolay Kislov, Elaine T. Lam, Eric G. Voog, Lance C. Pagliaro, Laurence Albiges, John B.A.G. Haanen, James Larkin, Martin H. Voss, Brian I. Rini, Mehmet A. Bilen
Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0996067052999fa15e2f911fc0f615
https://doi.org/10.1158/1078-0432.22482989.v1
https://doi.org/10.1158/1078-0432.22482989.v1
Autor:
Simon Chowdhury, Tony Golsorkhi, Simon P. Watkins, Foad Green, Melanie Dowson, Darrin Despain, Andrea Loehr, Andrew D. Simmons, Felix Y. Feng, Charles J. Ryan, Laurence E. Krieger, Celestia S. Higano, Axel S. Merseburger, Karim Fizazi, Josep Maria Piulats, Jingsong Zhang, Julie Rowe, Francesco Ricci, Ray McDermott, Alan H. Bryce, Eric G. Voog, Nicholas J. Vogelzang, Brieuc Sautois, Jeremy D. Shapiro, Akash Patnaik, David Campbell, Wassim Abida
Supplementary Figure S2. Summary of observed alterations in CHEK2 (C).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027609baa21aea9557699de9d72c6a16
https://doi.org/10.1158/1078-0432.22478691.v1
https://doi.org/10.1158/1078-0432.22478691.v1